Review



human m6a epitranscriptomic microarray (8 × 60 k)  (Arraystar inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Arraystar inc human m6a epitranscriptomic microarray (8 × 60 k)
    Reduced <t>m6A</t> level in LUAD. (A) The global m6A level of total RNAs in six paired LUAD patient tumor tissues (Tumor) and matched adjacent non-tumor tissues (Normal). (B–E) The relative expression of METTL3, METTL14, ALKBH5 and FTO mRNA in six paired LUAD tissues compared with those in adjacent non-tumor tissues. (F) Western blot showing the protein expression of METTL3, METTL14, ALKBH5 and FTO in LUAD tissues (T) and adjacent non-tumor tissues (N). (G) Relative protein levels calculated based on the band density in western blot results. * P < 0.05, ** P < 0.01, and **** P < 0.0001.
    Human M6a Epitranscriptomic Microarray (8 × 60 K), supplied by Arraystar inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human m6a epitranscriptomic microarray (8 × 60 k)/product/Arraystar inc
    Average 90 stars, based on 1 article reviews
    human m6a epitranscriptomic microarray (8 × 60 k) - by Bioz Stars, 2026-06
    90/100 stars

    Images

    1) Product Images from "N6-Methyladenosine-Regulated mRNAs: Potential Prognostic Biomarkers for Patients With Lung Adenocarcinoma"

    Article Title: N6-Methyladenosine-Regulated mRNAs: Potential Prognostic Biomarkers for Patients With Lung Adenocarcinoma

    Journal: Frontiers in Cell and Developmental Biology

    doi: 10.3389/fcell.2021.705962

    Reduced m6A level in LUAD. (A) The global m6A level of total RNAs in six paired LUAD patient tumor tissues (Tumor) and matched adjacent non-tumor tissues (Normal). (B–E) The relative expression of METTL3, METTL14, ALKBH5 and FTO mRNA in six paired LUAD tissues compared with those in adjacent non-tumor tissues. (F) Western blot showing the protein expression of METTL3, METTL14, ALKBH5 and FTO in LUAD tissues (T) and adjacent non-tumor tissues (N). (G) Relative protein levels calculated based on the band density in western blot results. * P < 0.05, ** P < 0.01, and **** P < 0.0001.
    Figure Legend Snippet: Reduced m6A level in LUAD. (A) The global m6A level of total RNAs in six paired LUAD patient tumor tissues (Tumor) and matched adjacent non-tumor tissues (Normal). (B–E) The relative expression of METTL3, METTL14, ALKBH5 and FTO mRNA in six paired LUAD tissues compared with those in adjacent non-tumor tissues. (F) Western blot showing the protein expression of METTL3, METTL14, ALKBH5 and FTO in LUAD tissues (T) and adjacent non-tumor tissues (N). (G) Relative protein levels calculated based on the band density in western blot results. * P < 0.05, ** P < 0.01, and **** P < 0.0001.

    Techniques Used: Expressing, Western Blot

    Overview of differentially m6A-methylated mRNAs in LUAD. (A) Volcano plot of differentially m6A-modified mRNAs based on log2FC > 0.5 and p -value < 0.05. (B,C) Heatmaps of the top 20 m6A hypo- and hypermethylated mRNAs in LUAD. Data are shown in green (m6A hypomethylation) to red (m6A hypermethylation). (D,E) Venn diagrams showing the overlapping hypo- and hypermethylated mRNAs between stage I samples and stage III samples. (F,G) Heat-maps of the two hypomethylated mRNAs and eight hypermethylated mRNAs between stage I samples and stage III samples.
    Figure Legend Snippet: Overview of differentially m6A-methylated mRNAs in LUAD. (A) Volcano plot of differentially m6A-modified mRNAs based on log2FC > 0.5 and p -value < 0.05. (B,C) Heatmaps of the top 20 m6A hypo- and hypermethylated mRNAs in LUAD. Data are shown in green (m6A hypomethylation) to red (m6A hypermethylation). (D,E) Venn diagrams showing the overlapping hypo- and hypermethylated mRNAs between stage I samples and stage III samples. (F,G) Heat-maps of the two hypomethylated mRNAs and eight hypermethylated mRNAs between stage I samples and stage III samples.

    Techniques Used: Methylation, Modification

    Functional enrichment of differentially m6A methylated mRNAs. (A) KEGG pathway enrichment analysis of hypo- and hypermethylated mRNAs. (B,C) Gene ontology (GO) enrichment analysis of the m6A hypermethylated and hypomethylated mRNAs.
    Figure Legend Snippet: Functional enrichment of differentially m6A methylated mRNAs. (A) KEGG pathway enrichment analysis of hypo- and hypermethylated mRNAs. (B,C) Gene ontology (GO) enrichment analysis of the m6A hypermethylated and hypomethylated mRNAs.

    Techniques Used: Functional Assay, Methylation

    Integration of m6A methylation and mRNA expression data to obtain m6A-regulated mRNAs. (A) Four-quadrant plots to show the mRNAs with a significant change both in m6A and mRNA levels. (B) Bubble plot showing the mRNA expression levels and m6A modification levels of m6A-regulated mRNAs.
    Figure Legend Snippet: Integration of m6A methylation and mRNA expression data to obtain m6A-regulated mRNAs. (A) Four-quadrant plots to show the mRNAs with a significant change both in m6A and mRNA levels. (B) Bubble plot showing the mRNA expression levels and m6A modification levels of m6A-regulated mRNAs.

    Techniques Used: Methylation, Expressing, Modification

    Evaluation of the prognostic performance of the m6A-regulated mRNAs. (A–C) Least absolute shrinkage and selection operator (LASSO) regression was performed to calculate the minimum criteria (A,B) and coefficients (C) . (D,G) Kaplan–Meier survival analysis of high-risk (red) and low-risk (blue) LUAD patients in the training set and validation set. (E,H) The receiver operating characteristic curve (ROC) analysis for the prognosis prediction of the signature of overall survival (OS) in the training set and validation set and the area under curve (AUC) was calculated. (F,I) Distributions of risk scores and survival status of LUAD patients in the training set and validation set.
    Figure Legend Snippet: Evaluation of the prognostic performance of the m6A-regulated mRNAs. (A–C) Least absolute shrinkage and selection operator (LASSO) regression was performed to calculate the minimum criteria (A,B) and coefficients (C) . (D,G) Kaplan–Meier survival analysis of high-risk (red) and low-risk (blue) LUAD patients in the training set and validation set. (E,H) The receiver operating characteristic curve (ROC) analysis for the prognosis prediction of the signature of overall survival (OS) in the training set and validation set and the area under curve (AUC) was calculated. (F,I) Distributions of risk scores and survival status of LUAD patients in the training set and validation set.

    Techniques Used: Selection, Biomarker Discovery

    Prognostic analysis of the m6A-RPS. (A,B) Univariate and multivariate Cox regression analysis of correlations between risk score for m6A-RPS and clinical parameters in the training set and validation set. (C,D) Kaplan–Meier survival analysis of m6A-RPS prognostic value in LUAD stage I–II and stage III–IV cases in the TCGA cohort.
    Figure Legend Snippet: Prognostic analysis of the m6A-RPS. (A,B) Univariate and multivariate Cox regression analysis of correlations between risk score for m6A-RPS and clinical parameters in the training set and validation set. (C,D) Kaplan–Meier survival analysis of m6A-RPS prognostic value in LUAD stage I–II and stage III–IV cases in the TCGA cohort.

    Techniques Used: Biomarker Discovery

    Principal Component Analysis. (A) Forest plot of the prognostic ability of the 10 m6A-regulated mRNAs included in the prognostic signature. (B) Heatmap of the 10 m6A-regulated mRNA expression levels with different clinicopathological features. (C,D) Overall survival curves according to RFXAP and KHDRBS2 mRNA expression in TCGA LUAD patient cohorts. The mRNA expression level (E,F), m6A methylation level (G,H) and protein expression level (I) of RFXAP and KHDRBS2 in LUAD in LUAD tissues (Tumor) and adjacent non-tumor tissues (Normal). * P < 0.05, ** P < 0.01, and *** P < 0.001.
    Figure Legend Snippet: Principal Component Analysis. (A) Forest plot of the prognostic ability of the 10 m6A-regulated mRNAs included in the prognostic signature. (B) Heatmap of the 10 m6A-regulated mRNA expression levels with different clinicopathological features. (C,D) Overall survival curves according to RFXAP and KHDRBS2 mRNA expression in TCGA LUAD patient cohorts. The mRNA expression level (E,F), m6A methylation level (G,H) and protein expression level (I) of RFXAP and KHDRBS2 in LUAD in LUAD tissues (Tumor) and adjacent non-tumor tissues (Normal). * P < 0.05, ** P < 0.01, and *** P < 0.001.

    Techniques Used: Expressing, Methylation

    Co-expression and interaction network analyses between m6A regulators and m6A-RPS. (A) Spearman correlation analysis and (B) co-expression network of m6A RNA methylation regulators, methyltransferases (METTL3, METTL14, METTL16, and WTAP), demethylases (FTO and ALKBH5) and 10 m6A-regulated mRNAs in the prognostic signature in TCGA LUAD patient cohorts.
    Figure Legend Snippet: Co-expression and interaction network analyses between m6A regulators and m6A-RPS. (A) Spearman correlation analysis and (B) co-expression network of m6A RNA methylation regulators, methyltransferases (METTL3, METTL14, METTL16, and WTAP), demethylases (FTO and ALKBH5) and 10 m6A-regulated mRNAs in the prognostic signature in TCGA LUAD patient cohorts.

    Techniques Used: Expressing, Methylation



    Similar Products

    human m6a epitranscriptomic microarray (8 × 60 k)  (Arraystar inc)
    90
    Arraystar inc human m6a epitranscriptomic microarray (8 × 60 k)
    Reduced <t>m6A</t> level in LUAD. (A) The global m6A level of total RNAs in six paired LUAD patient tumor tissues (Tumor) and matched adjacent non-tumor tissues (Normal). (B–E) The relative expression of METTL3, METTL14, ALKBH5 and FTO mRNA in six paired LUAD tissues compared with those in adjacent non-tumor tissues. (F) Western blot showing the protein expression of METTL3, METTL14, ALKBH5 and FTO in LUAD tissues (T) and adjacent non-tumor tissues (N). (G) Relative protein levels calculated based on the band density in western blot results. * P < 0.05, ** P < 0.01, and **** P < 0.0001.
    Human M6a Epitranscriptomic Microarray (8 × 60 K), supplied by Arraystar inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human m6a epitranscriptomic microarray (8 × 60 k)/product/Arraystar inc
    Average 90 stars, based on 1 article reviews
    human m6a epitranscriptomic microarray (8 × 60 k) - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Reduced m6A level in LUAD. (A) The global m6A level of total RNAs in six paired LUAD patient tumor tissues (Tumor) and matched adjacent non-tumor tissues (Normal). (B–E) The relative expression of METTL3, METTL14, ALKBH5 and FTO mRNA in six paired LUAD tissues compared with those in adjacent non-tumor tissues. (F) Western blot showing the protein expression of METTL3, METTL14, ALKBH5 and FTO in LUAD tissues (T) and adjacent non-tumor tissues (N). (G) Relative protein levels calculated based on the band density in western blot results. * P < 0.05, ** P < 0.01, and **** P < 0.0001.

    Journal: Frontiers in Cell and Developmental Biology

    Article Title: N6-Methyladenosine-Regulated mRNAs: Potential Prognostic Biomarkers for Patients With Lung Adenocarcinoma

    doi: 10.3389/fcell.2021.705962

    Figure Lengend Snippet: Reduced m6A level in LUAD. (A) The global m6A level of total RNAs in six paired LUAD patient tumor tissues (Tumor) and matched adjacent non-tumor tissues (Normal). (B–E) The relative expression of METTL3, METTL14, ALKBH5 and FTO mRNA in six paired LUAD tissues compared with those in adjacent non-tumor tissues. (F) Western blot showing the protein expression of METTL3, METTL14, ALKBH5 and FTO in LUAD tissues (T) and adjacent non-tumor tissues (N). (G) Relative protein levels calculated based on the band density in western blot results. * P < 0.05, ** P < 0.01, and **** P < 0.0001.

    Article Snippet: After merging, it was hybridized to the Arraystar Human m6A Epitranscriptomic Microarray (8 × 60 K).

    Techniques: Expressing, Western Blot

    Overview of differentially m6A-methylated mRNAs in LUAD. (A) Volcano plot of differentially m6A-modified mRNAs based on log2FC > 0.5 and p -value < 0.05. (B,C) Heatmaps of the top 20 m6A hypo- and hypermethylated mRNAs in LUAD. Data are shown in green (m6A hypomethylation) to red (m6A hypermethylation). (D,E) Venn diagrams showing the overlapping hypo- and hypermethylated mRNAs between stage I samples and stage III samples. (F,G) Heat-maps of the two hypomethylated mRNAs and eight hypermethylated mRNAs between stage I samples and stage III samples.

    Journal: Frontiers in Cell and Developmental Biology

    Article Title: N6-Methyladenosine-Regulated mRNAs: Potential Prognostic Biomarkers for Patients With Lung Adenocarcinoma

    doi: 10.3389/fcell.2021.705962

    Figure Lengend Snippet: Overview of differentially m6A-methylated mRNAs in LUAD. (A) Volcano plot of differentially m6A-modified mRNAs based on log2FC > 0.5 and p -value < 0.05. (B,C) Heatmaps of the top 20 m6A hypo- and hypermethylated mRNAs in LUAD. Data are shown in green (m6A hypomethylation) to red (m6A hypermethylation). (D,E) Venn diagrams showing the overlapping hypo- and hypermethylated mRNAs between stage I samples and stage III samples. (F,G) Heat-maps of the two hypomethylated mRNAs and eight hypermethylated mRNAs between stage I samples and stage III samples.

    Article Snippet: After merging, it was hybridized to the Arraystar Human m6A Epitranscriptomic Microarray (8 × 60 K).

    Techniques: Methylation, Modification

    Functional enrichment of differentially m6A methylated mRNAs. (A) KEGG pathway enrichment analysis of hypo- and hypermethylated mRNAs. (B,C) Gene ontology (GO) enrichment analysis of the m6A hypermethylated and hypomethylated mRNAs.

    Journal: Frontiers in Cell and Developmental Biology

    Article Title: N6-Methyladenosine-Regulated mRNAs: Potential Prognostic Biomarkers for Patients With Lung Adenocarcinoma

    doi: 10.3389/fcell.2021.705962

    Figure Lengend Snippet: Functional enrichment of differentially m6A methylated mRNAs. (A) KEGG pathway enrichment analysis of hypo- and hypermethylated mRNAs. (B,C) Gene ontology (GO) enrichment analysis of the m6A hypermethylated and hypomethylated mRNAs.

    Article Snippet: After merging, it was hybridized to the Arraystar Human m6A Epitranscriptomic Microarray (8 × 60 K).

    Techniques: Functional Assay, Methylation

    Integration of m6A methylation and mRNA expression data to obtain m6A-regulated mRNAs. (A) Four-quadrant plots to show the mRNAs with a significant change both in m6A and mRNA levels. (B) Bubble plot showing the mRNA expression levels and m6A modification levels of m6A-regulated mRNAs.

    Journal: Frontiers in Cell and Developmental Biology

    Article Title: N6-Methyladenosine-Regulated mRNAs: Potential Prognostic Biomarkers for Patients With Lung Adenocarcinoma

    doi: 10.3389/fcell.2021.705962

    Figure Lengend Snippet: Integration of m6A methylation and mRNA expression data to obtain m6A-regulated mRNAs. (A) Four-quadrant plots to show the mRNAs with a significant change both in m6A and mRNA levels. (B) Bubble plot showing the mRNA expression levels and m6A modification levels of m6A-regulated mRNAs.

    Article Snippet: After merging, it was hybridized to the Arraystar Human m6A Epitranscriptomic Microarray (8 × 60 K).

    Techniques: Methylation, Expressing, Modification

    Evaluation of the prognostic performance of the m6A-regulated mRNAs. (A–C) Least absolute shrinkage and selection operator (LASSO) regression was performed to calculate the minimum criteria (A,B) and coefficients (C) . (D,G) Kaplan–Meier survival analysis of high-risk (red) and low-risk (blue) LUAD patients in the training set and validation set. (E,H) The receiver operating characteristic curve (ROC) analysis for the prognosis prediction of the signature of overall survival (OS) in the training set and validation set and the area under curve (AUC) was calculated. (F,I) Distributions of risk scores and survival status of LUAD patients in the training set and validation set.

    Journal: Frontiers in Cell and Developmental Biology

    Article Title: N6-Methyladenosine-Regulated mRNAs: Potential Prognostic Biomarkers for Patients With Lung Adenocarcinoma

    doi: 10.3389/fcell.2021.705962

    Figure Lengend Snippet: Evaluation of the prognostic performance of the m6A-regulated mRNAs. (A–C) Least absolute shrinkage and selection operator (LASSO) regression was performed to calculate the minimum criteria (A,B) and coefficients (C) . (D,G) Kaplan–Meier survival analysis of high-risk (red) and low-risk (blue) LUAD patients in the training set and validation set. (E,H) The receiver operating characteristic curve (ROC) analysis for the prognosis prediction of the signature of overall survival (OS) in the training set and validation set and the area under curve (AUC) was calculated. (F,I) Distributions of risk scores and survival status of LUAD patients in the training set and validation set.

    Article Snippet: After merging, it was hybridized to the Arraystar Human m6A Epitranscriptomic Microarray (8 × 60 K).

    Techniques: Selection, Biomarker Discovery

    Prognostic analysis of the m6A-RPS. (A,B) Univariate and multivariate Cox regression analysis of correlations between risk score for m6A-RPS and clinical parameters in the training set and validation set. (C,D) Kaplan–Meier survival analysis of m6A-RPS prognostic value in LUAD stage I–II and stage III–IV cases in the TCGA cohort.

    Journal: Frontiers in Cell and Developmental Biology

    Article Title: N6-Methyladenosine-Regulated mRNAs: Potential Prognostic Biomarkers for Patients With Lung Adenocarcinoma

    doi: 10.3389/fcell.2021.705962

    Figure Lengend Snippet: Prognostic analysis of the m6A-RPS. (A,B) Univariate and multivariate Cox regression analysis of correlations between risk score for m6A-RPS and clinical parameters in the training set and validation set. (C,D) Kaplan–Meier survival analysis of m6A-RPS prognostic value in LUAD stage I–II and stage III–IV cases in the TCGA cohort.

    Article Snippet: After merging, it was hybridized to the Arraystar Human m6A Epitranscriptomic Microarray (8 × 60 K).

    Techniques: Biomarker Discovery

    Principal Component Analysis. (A) Forest plot of the prognostic ability of the 10 m6A-regulated mRNAs included in the prognostic signature. (B) Heatmap of the 10 m6A-regulated mRNA expression levels with different clinicopathological features. (C,D) Overall survival curves according to RFXAP and KHDRBS2 mRNA expression in TCGA LUAD patient cohorts. The mRNA expression level (E,F), m6A methylation level (G,H) and protein expression level (I) of RFXAP and KHDRBS2 in LUAD in LUAD tissues (Tumor) and adjacent non-tumor tissues (Normal). * P < 0.05, ** P < 0.01, and *** P < 0.001.

    Journal: Frontiers in Cell and Developmental Biology

    Article Title: N6-Methyladenosine-Regulated mRNAs: Potential Prognostic Biomarkers for Patients With Lung Adenocarcinoma

    doi: 10.3389/fcell.2021.705962

    Figure Lengend Snippet: Principal Component Analysis. (A) Forest plot of the prognostic ability of the 10 m6A-regulated mRNAs included in the prognostic signature. (B) Heatmap of the 10 m6A-regulated mRNA expression levels with different clinicopathological features. (C,D) Overall survival curves according to RFXAP and KHDRBS2 mRNA expression in TCGA LUAD patient cohorts. The mRNA expression level (E,F), m6A methylation level (G,H) and protein expression level (I) of RFXAP and KHDRBS2 in LUAD in LUAD tissues (Tumor) and adjacent non-tumor tissues (Normal). * P < 0.05, ** P < 0.01, and *** P < 0.001.

    Article Snippet: After merging, it was hybridized to the Arraystar Human m6A Epitranscriptomic Microarray (8 × 60 K).

    Techniques: Expressing, Methylation

    Co-expression and interaction network analyses between m6A regulators and m6A-RPS. (A) Spearman correlation analysis and (B) co-expression network of m6A RNA methylation regulators, methyltransferases (METTL3, METTL14, METTL16, and WTAP), demethylases (FTO and ALKBH5) and 10 m6A-regulated mRNAs in the prognostic signature in TCGA LUAD patient cohorts.

    Journal: Frontiers in Cell and Developmental Biology

    Article Title: N6-Methyladenosine-Regulated mRNAs: Potential Prognostic Biomarkers for Patients With Lung Adenocarcinoma

    doi: 10.3389/fcell.2021.705962

    Figure Lengend Snippet: Co-expression and interaction network analyses between m6A regulators and m6A-RPS. (A) Spearman correlation analysis and (B) co-expression network of m6A RNA methylation regulators, methyltransferases (METTL3, METTL14, METTL16, and WTAP), demethylases (FTO and ALKBH5) and 10 m6A-regulated mRNAs in the prognostic signature in TCGA LUAD patient cohorts.

    Article Snippet: After merging, it was hybridized to the Arraystar Human m6A Epitranscriptomic Microarray (8 × 60 K).

    Techniques: Expressing, Methylation